To view the PDF file, sign up for a MySharenet subscription.

MEDICLINIC INTERNATIONAL PLC - Posting of annual report and financial statements, notice of annual general meeting and proxy form

Release Date: 21/06/2022 16:00
Code(s): MEI     PDF:  
Wrap Text
Posting of annual report and financial statements, notice of annual general meeting and proxy form

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
LEI: 2138002S5BSBIZTD5I60
(‘Mediclinic’, or the ‘Company’, or the ‘Group’)

21 June 2022


Mediclinic announces today the publication of its Annual Report and Financial Statements in respect
of the financial year ended 31 March 2022 (the ‘2022 Annual Report’) and notice of the Company’s
2022 annual general meeting (the ‘AGM’) (the ‘Notice’).

The 2022 Annual Report is being made available on the Group’s annual reporting website at:, together with the Notice and the Group’s 2022 Clinical Services and
Sustainable Development reports.

Shareholders who elected to receive shareholder information electronically are being notified that
these documents are available on the Company's website and hard copies of the documents are
being posted today to shareholders who elected to receive shareholder information in hard copy.

Arrangements for the AGM and Shareholder Event

The AGM will be held on Thursday, 28 July 2022, at 15:00 BST at the Rosewood London Hotel, 252
High Holborn, London, WC1V 7EN, United Kingdom (‘UK’).

Shareholders are invited to attend and participate at the AGM in person; however, to ensure all
shareholders have the opportunity to engage with the Board before submitting their proxy votes,
there will be a live online shareholder engagement event on Thursday, 14 July 2022, at 14:00 BST.
Further information can be found in the Notice.

The Company will continue to monitor the status of the pandemic and will revise arrangements in
connection with the AGM or introduce COVID-safe measures should it become necessary. Any
changes to the arrangements for the AGM (including any change to the location of the AGM) will be
communicated to shareholders before the meeting via the Company’s website
( and a regulatory news announcement.

In compliance with JSE requirements, for shareholders on the South African Branch Register: (i) the
record date for the purpose of determining which shareholders are entitled to participate in and vote
at the AGM is close of business on Tuesday, 26 July 2022; and (ii) the last day to trade in the
Company’s shares in order to be recorded as a shareholder by the voting record date is Thursday,
21 July 2022.

Further information

In accordance with the Financial Conduct Authority’s Listing Rule 9.6.1 and DTRs 4.1.14 and 6.2.2,
the 2022 Annual Report has been submitted in the required structured reporting format to the
National Storage Mechanism, together with the Notice. Both are available for viewing at:

In accordance with DTR 6.3.5(1A), the regulated information required by DTR 6.3.5 is available in
full unedited text within the 2022 Annual Report uploaded to the National Storage Mechanism.

Mediclinic announced its final results for the year ended 31 March 2022 on 25 May 2022 (RNS
Number: 6674M).

About Mediclinic International plc

Mediclinic is a diversified international private healthcare services group, established in South Africa
in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle

The Group's core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the
continuum of care in such a way that the Group will be regarded as the most respected and trusted
provider of healthcare services by patients, medical practitioners, funders and regulators of
healthcare in each of its markets.

At 31 March 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health
facilities, 20 day case clinics and 20 outpatient clinics. The Swiss operations included 17 hospitals
and four day case clinics with around 1 900 inpatient beds; Southern Africa operations included 50
hospitals (three of which in Namibia), five subacute hospitals, two mental health facilities and 14 day
case clinics (four of which operated by Intercare) across South Africa, and around 8 650 inpatient
beds; and the Middle East operated seven hospitals, two day case clinics and 20 outpatient clinics
with around 1 000 inpatient beds in the UAE. In addition, under management contract the Middle
East will open a 200-bed hospital in the Kingdom of Saudi Arabia in 2023.

The Company's primary listing is on the London Stock Exchange ('LSE') in the UK, with secondary
listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare
group based in the UK and listed on the LSE.

For further information, please contact:

Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)333 300 1930

Investor queries
James Arnold, Head of Investor Relations, Mediclinic International plc
+44 (0)20 3786 8181

Media queries
FTI Consulting
Ben Atwell/Ciara Martin - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, UK
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd

Date: 21-06-2022 04:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story